If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
53
results.
Updated on
03/10/2025 [06:45:00]
Absstract of: US2025306026A1
This disclosure relates to the surprising and unexpected finding that the well-known cancer protein, Myeloid Cell Leukemia-1 (MCL-1), binds to and modulates the enzymatic activity of Very Long Chain Acyl CoA Dehydrogenase (VLCAD), thereby regulating fatty acid β-oxidation. This finding is employed in compositions and methods of treating cancer, metabolic diseases, or other conditions characterized by excessive fatty acid β-oxidation by blocking or reducing the energy production of cells (e.g., cancer) through inhibiting the MCL-1/VLCAD interaction and/or directly inhibiting VLCAD enzymatic activity. In addition, the disclosure features methods for identifying such agents that inhibit the interaction between MCL-1 and VLCAD or that inhibit VLCAD enzymatic activity.
Absstract of: AU2025230668A1
Disclosed are methods of treating a subject having high-risk multiple myeloma, methods of achieving negative minimal residual disease status in a subject having multiple myeloma, and methods of predicting a likelihood of, or decreasing a risk of, relapse and/or disease progression in a subject having multiple myeloma. Disclosed are methods of treating a subject having high-risk multiple myeloma, methods of achieving negative minimal residual disease status in a subject having multiple myeloma, and methods of predicting a likelihood of, or decreasing a risk of, relapse and/or disease progression in a subject having multiple myeloma. ep i s c l o s e d a r e m e t h o d s o f t r e a t i n g a s u b j e c t h a v i n g h i g h - r i s k m u l t i p l e m y e l o m a , e p m e t h o d s o f a c h i e v i n g n e g a t i v e m i n i m a l r e s i d u a l d i s e a s e s t a t u s i n a s u b j e c t h a v i n g m u l t i p l e m y e l o m a , a n d m e t h o d s o f p r e d i c t i n g a l i k e l i h o o d o f , o r d e c r e a s i n g a r i s k o f , r e l a p s e a n d o r d i s e a s e p r o g r e s s i o n i n a s u b j e c t h a v i n g m u l t i p l e m y e l o m a
Absstract of: AU2025230686A1
The present invention provides a vaccine for feline leukemia virus and methods of making and using the vaccine alone, or in combinations with other protective agents. 5 The present invention provides a vaccine for feline leukemia virus and methods of making and using the vaccine alone, or in combinations with other 5 protective agents. ep h e p r e s e n t i n v e n t i o n p r o v i d e s a v a c c i n e f o r f e l i n e l e u k e m i a v i r u s a n d e p m e t h o d s o f m a k i n g a n d u s i n g t h e v a c c i n e a l o n e , o r i n c o m b i n a t i o n s w i t h o t h e r p r o t e c t i v e a g e n t s
Absstract of: US2025305071A1
A method for detecting conjunctival diseases such as conjunctival MALT lymphoma, and an aging biomarker that serves as an indicator of the aging state of a subject are provided. The method for detecting conjunctival diseases comprises a step of comparing a microbial community structure of a microbiota in an ocular surface tissue specimen sampled from a healthy person with a microbial community structure of a microbiota in an ocular surface tissue specimen sampled from a subject to determine that the ocular surface tissue specimen of the subject has an indication of the conjunctival diseases. The aging biomarker comprises bacterial species which belongs to the Corynebacteriaceae family or the Propionibacteriales family in an ocular surface tissue.
Absstract of: WO2024110405A1
Upon EBV infection, the inventors found that IL-27 is produced by infected B lymphocytes and IL27RAIL-27 interaction is required for in vitro maintenance and expansion of EBV-transformed B cells, potentially explaining the favorable outcome of the EBV viral disease in IL27RA-deficient patients. In addition, the inventors identified neutralizing anti-IL27 autoantibodies in individuals who developed sporadic infectious mononucleosis, thus possibly phenocopying the IL27RA deficiency. Collectively, these results demonstrate the critical role of IL27-IL27RA axis in immunity to EBV, but also the hijacking of this defense by EBV to promote expansion of infected cells. The IL27-IL27RA could therefore represent a novel therapeutic target to inhibit EBV-driven B lymphoproliferative diseases.
Absstract of: WO2024108303A1
Lymphoid leukemia such as acute lymphoblastic leukemia (ALL) represents a devastating disease especially when it occurs in adults. While dose-intensification strategies have led to a significant improvement in outcomes for pediatric patients, prognosis for the elderly remains very poor, with only 30-40% of adult patients with ALL achieving long-term remission. Novel tumor-specific antigens (TSAs) shared by a large proportion of lymphoid leukemia cells are described herein. Most of the TSAs described herein derives from aberrantly expressed unmutated genomic sequences, such as intronic and intergenic sequences, which are not expressed in normal tissues. Nucleic acids, compositions, cells and vaccines derived from these TSAs are described. The use of the TSAs, nucleic acids, compositions, cells and vaccines for the treatment of leukemia such as lymphoid leukemia is also described.
Absstract of: WO2025199151A1
The present disclosure relates to compounds and compositions, and methods of uing the compounds and compositions for inducing the degradation of proteins that are relevant to cancer such as. for example. KDM4B and VCL. Also described are methods of treating cancer (e.g, a sarcoma, a carcinoma, a hematological cancer, a solid tumor, breast cancer, cervical cancer, gastrointestinal cancer, colorectal cancer, brain cancer, skin cancer, prostate cancer, ovarian cancer, non-small cell lung carcinoma, thyroid cancer, testicular cancer, pancreatic cancer, liver cancer, endometrial cancer, melanoma, glioma, leukemia, lymphoma, chronic myeloproliferative disorder, myelodysplastic syndrome, myeloproliferative neoplasm, plasma cell neoplasm (myeloma)) using the disclosed compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.
Absstract of: US2025295771A1
Provided herein are uses of T cells, e.g., chimeric antigen receptor (CAR) T cells, for treating a tumor or a cancer (such as B cell related cancer, e.g., multiple myeloma) wherein the subject being treated has previously received a topoisomerase inhibitor, a proteasome inhibitor, an anti-CD38 agent, an immunomodulatory agent, or an anti-SLAMF agent therapy.
Absstract of: US2025299796A1
Provided herein are methods and immune biomarkers that identify progression and treatment options for hematological malignancies (e.g., smoldering multiple myeloma (SMM), monoclonal gammopathy of undetermined significance (MGUS), or multiple myeloma (MM)). Also provided are materials and methods for the prognosis, staging, and monitoring of SMM, MGUS, or MM based on the presence of the immune biomarkers in a sample (e.g., a blood sample or a bone marrow sample), as well as methods for monitoring the progression of SMM, MGUS, or MM, determining the efficacy of a therapeutic agent, determining a treatment for SMM, MGUS (e.g., before progression to MM), or MM, and/or treating SMM, MGUS, or MM. The methods provided herein provide several advantages over invasive biopsies.
Absstract of: AU2025230652A1
22046882_1 (GHMatters) P122730.AU.1 The present invention relates to RNAi agents, e.g., double stranded RNA (dsRNA) agents, targeting the Transmembrane protease, serine 6 (TMPRSS6) gene. The invention also relates to methods of using such RNAi agents to inhibit expression of a TMPRSS6 gene and to methods of preventing and treating a TMPRSS6-associated disorder, e.g., a disorder associated with iron overload and/or a disorder of ineffective erythropoiesis, e.g., hereditary hemochromatosis, β- thalassemia (e.g., β-thalassemia major and β-thalassemia intermedia), polycythemia vera, myelodysplastic syndrome, congenital dyserythropoietic anemias, pyruvate kinase deficiency, erythropoietic porphyria, parkinson’s Disease, Alzheimer’s Disease or Friedreich’s Ataxia. The present invention relates to RNAi agents, e.g., double stranded RNA (dsRNA) agents, targeting the Transmembrane protease, serine 6 (TMPRSS6) gene. The invention also relates to methods of using such RNAi agents to inhibit expression of a TMPRSS6 gene and to methods of preventing and treating a TMPRSS6-associated disorder, e.g., a disorder associated with iron overload and/or a disorder of ineffective erythropoiesis, e.g., hereditary hemochromatosis, ß- thalassemia (e.g., ß-thalassemia major and ß-thalassemia intermedia), polycythemia vera, myelodysplastic syndrome, congenital dyserythropoietic anemias, pyruvate kinase deficiency, erythropoietic porphyria, parkinson's Disease, Alzheimer's Disease or Friedre
Absstract of: AU2024232412A1
An aqueous pharmaceutical formulation having improved stability includes denosumab and a poloxamer, and preferably a histidine buffer and/or sugar or sugar alcohol. The formulation is for use in treating or preventing osteoporosis, loss of bone mass, skeletal-related events associated with multiple myeloma, solid tumor bone metastases, giant cell tumors of the bone or hypercalcemia.
Absstract of: WO2025189988A1
Provided is use of a monophosphate deoxyribose fluorouracil nucleoside prodrug in the preparation of a drug for preventing and/or treating tumors. The monophosphate deoxyribose fluorouracil nucleoside prodrug is a derivative formed by substituting at least one thymine in nucleolin aptamer AS1411 with fluorouracil. The tumors include at least one of lung cancer, breast cancer, prostate cancer, pancreatic cancer, kidney cancer, cervical cancer, leukemia and lymphoma, melanoma, glioblastoma, neuroblastoma, sarcoma, and gastric cancer. The monophosphate deoxyribose fluorouracil nucleoside prodrug binds to the nucleolin protein and selectively enters tumor cells under the action of the nucleolin protein, and release an antimetabolite to inhibit thymine nucleotide synthase, thereby achieving an anti-tumor effect.
Absstract of: WO2025194094A1
This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of carbothioamide (and structurally related) small-molecule compounds which function as inhibitors of SIRT5, and their use as therapeutics for the treatment of diseases associated with posttranslational modification functions (e.g., diseases associated with SIRT5 activity) (e.g., cancer (e.g., melanoma, non-small cell lung cancer (NSCLC), hepatocellular carcinoma (HCC), ovarian cancer, colorectal cancer (CRC), acute myeloid leukemia (AML), Ewing's sarcoma, brain cancer, pancreatic cancer, renal cancer, breast cancer, prostate cancer, lung cancer, leukemia and lymphoma), diabetes, autoimmune diseases, inflammatory diseases, fibrotic diseases, cardiovascular diseases, and neurodegenerative diseases).
Absstract of: WO2025191110A1
The invention relates to an in vitro method for establishing the prognosis of a subject diagnosed as suffering or having suffered from a diffuse large B-cell lymphoma and including: - an identification step of at least two markers comprising 2-aminobutyrate or its acid derivative thereof and LDL-1 lipoprotein optionally in combination with at least one marker selected from : 2-hydroxybutyrate or its acid derivative thereof, 3-hydroxybutyrate or its acid derivative thereof, LDL-2 lipoprotein, LDL-1-CH lipoprotein, LDL-1 lipoprotein phospholipids, the Apo-B subfraction of LDL-1 lipoprotein, LDL-1 lipoprotein triglycerides, LDL-2 lipoprotein triglycerides, LDL-3 lipoprotein triglycerides, formic acid and acetyl acetic acid, identifying said at least two markers being the prognosis of, or a risk of, a bad clinical course of the diffuse large B-cell lymphoma in the subject.
Absstract of: US2025288669A1
A novel human T-cell acute lymphoblastic leukemia (T-ALL) cell line called INB16 (ATCC Deposit no. PTA-125809) induces memory like function on natural killer cells upon contact therewith, which memory like natural killer cells have demonstrated ability to identify and kill cancer cells, including hematologic and solid tumor cells. Useful applications of the INB16 cell line include research, a cancer therapeutic agent comprising replication incompetent INB16 cells and/or membrane portions thereof for in vivo administration and restoring function of a patient's own NK cells, and related methods of treating cancer.
Absstract of: AU2024253832A1
Aspects of the disclosure provide anti-TMPRSS6 antibodies and methods of using the same for promoting hepcidin expression, and treating iron overload associated conditions, such as hemochromatosis, sickle cell disease, thalassemia, hemolysis, Diamond-Blackfan anemia, myelodysplastic syndrome (MDS), blood transfusion.
Absstract of: WO2025193685A1
Provided herein are methods of treating a subject who has multiple myeloma and has received one to three prior treatment(s). Infusions of chimeric antigen receptor (CAR)-T cells comprising a CAR capable of specifically binding to an epitope of BCMA are administered to the subject.
Absstract of: US2025289806A1
Disclosed herein are novel compounds with STK17A inhibitory activity. The compounds may be used to treat proliferative disorders, including myelodysplastic syndrome and leukemia.
Absstract of: US2025289837A1
The present invention relates to compounds of formula (I), processes for their preparation, and pharmaceutical compositions containing them as the active ingredient. Compounds of the present invention may be useful as mitochondrial KV1.3 inhibitors (mitoKV1.3) to treat cancer diseases and the like, including breast, colon, and prostate tumors, melanoma, smooth muscle, and skeletal muscle cancer, chronic lymphocytic leukemia, glioblastoma, and pancreatic ductal adenocarcinoma.
Absstract of: US2025290148A1
Disclosed herein is a method for preventing or reversing CAR-T cell resistance and/or radioresistance in a relapsed and refractory diffuse large B-cell lymphoma (R/R DLBCL) of a subject, that involves assaying a sample from the subject for mRNA sequences of genes with roles in DNA damage, apoptosis, immune activation, and/or c-MYC signaling; detecting aberrant splicing in one or more of the mRNA sequences; and administering to the subject an antisense oligonucleotide (ASO) that prevents the aberrant splicing.
Absstract of: US2025290890A1
The present disclosure teaches a diagnostic home kit to detect midkine level in blood samples. The kit includes an analyte receiver to receive the blood sample. Further, the kit includes a cantilever biosensor coated with a piezoelectric material and may also be immobilized by Anaplastic Lymphoma Kinase (ALK) receptors configured to attach midkine from the blood sample. The cantilevers may deflect when midkine binds to the ALK receptors, and this deflection may be captured by the piezoelectric material transducing a signal corresponding to the attached midkine. Furthermore, the kit includes an amplifier to receive and amplify the transduced signal. Moreover, the kit includes a signal processor to process the amplified signals to determine the level of midkine in the received blood sample. Additionally, the kit includes an output display unit to display midkine level in the blood sample.
Absstract of: WO2024100250A1
In a first aspect, the invention relates to a combination of at least one menin inhibitor with at least one immunoproteasome inhibitor for use as medicament, preferably for use in the treatment of leukemia. A second aspect of the invention is related to a pharmaceutical preparation comprising at least one menin inhibitor and at least one immunoproteasome inhibitor, optionally one or more pharmaceutically acceptable carrier(s) and optionally one or more pharmaceutically acceptable adjuvant(s).
Absstract of: MX2025005311A
The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer, in particular of hematological neoplasms, such as acute myeloid leukemia (AML). The present invention furthermore relates to tumor-associated T-cell peptide epitopes that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
Absstract of: MX2025005421A
A pharmaceutical combination includes a beta-lactam antibiotic alone or in combination with a beta-lactamase inhibitor useful for treating multiple myeloma, monoclonal gammopathy of undetermined significance, and smoldering multiple myeloma. A method for treating multiple myeloma, monoclonal gammopathy of undetermined significance, or smoldering multiple myeloma includes administering to a patient in need thereof an effective amount of a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor. Beta-lactam antibiotic for use in combination with a beta-lactamase inhibitor for the treatment of multiple myeloma, monoclonal gammopathy of undetermined significance, or smoldering multiple myeloma in a patient in need of the treatment is also described.
Nº publicación: EP4617665A1 17/09/2025
Applicant:
CENTRE NAT RECH SCIENT [FR]
UNIV PARIS CITE [FR]
INST NAT SANTE RECH MED [FR]
Centre National de la Recherche Scientifique,
Universit\u00E9 Paris Cit\u00E9,
Institut National de la Sant\u00E9 et de la Recherche M\u00E9dicale
Absstract of: EP4617665A1
The invention relates to an in vitro method for establishing the prognosis of a subject diagnosed as suffering or having suffered from a diffuse large B-cell lymphoma and including:- an identification step of at least two markers selected from : 2-aminobutyrate or its acid derivative thereof, 2-hydroxybutyrate or its acid derivative thereof, 3-hydroxybutyrate or its acid derivative thereof, LDL-1 lipoprotein, LDL-2 lipoprotein, LDL-1-CH lipoprotein, LDL-1 lipoprotein phospholipids, the Apo-B subfraction of LDL-1 lipoprotein, LDL-1 lipoprotein triglycerides, LDL-2 lipoprotein triglycerides, LDL-3 lipoprotein triglycerides, formic acid and acetyl acetic acid, identifying said at least two markers being the prognosis of, or a risk of, a bad clinical course of the diffuse large B-cell lymphoma in the subject.
BOPI
Electronic site
